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a  b  s  t  r  a  c  t
Rhomboid-family  intramembrane  serine  proteases  are  evolutionarily  widespread.  Their  functions  in  dif-
ferent  organisms  are  gradually  being  uncovered  and  already  suggest  medical  relevance  for  infectious
diseases  and  cancer.  In contrast  to  these  advances,  selective  inhibitors  that  could  serve  as  efﬁcient  tools  for
investigation  of  physiological  functions  of  rhomboids,  validation  of  their  disease  relevance  or  as templates
for  drug  development  are  lacking.  In this  review  I extract  what  is  known  about  rhomboid  protease  mech-eywords:
homboid protease
nhibitor
isease
echanism
anism  and  speciﬁcity,  examine  the  currently  used  inhibitors,  their  mechanism  of  action  and  limitations,
and  conclude  by  proposing  routes  for  future  development  of  rhomboid  protease  inhibitors.
© 2016  The  Author.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).ubstrate speciﬁcity
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The ﬁrst members of the rhomboid-like superfamily were iden-
iﬁed in Drosophila [1] as intramembrane serine proteases that
Abbreviations: ABP, activity based probe; ADAM17, a disintegrin and metallopro-
einase 17; cmk, chloromethylketone; cho, aldehyde; EGF, epidermal growth factor;
GFR, epidermal growth factor receptor; FRET, Foerster resonance energy transfer;
Rhom, inactive rhomboid homologue; PARL, presenilin-associated rhomboid-like;
D,  Parkinson’s disease; RHBDD, rhomboid domain-containing protein; RHBDL,
homboid-like protein; TNF, tumor necrosis factor ; TACE, TNF-converting
nzyme; TMD, transmembrane domain.
E-mail address: kvido.strisovsky@uochb.cas.cz
ttp://dx.doi.org/10.1016/j.semcdb.2016.08.021
084-9521/© 2016 The Author. Published by Elsevier Ltd. This is an open access article unactivate the ligands of the epidermal growth factor (EGF) recep-
tor [2]. Rhomboid protease homologs have since been found in
nearly every sequenced genome spanning virtually all life forms,
constituting the most widely occurring family of intramembrane
proteases [3]. More recently, a number of related but proteolyt-
ically inactive members of the superfamily have been identiﬁed,
such as iRhoms or Derlins [reviewed in [4]]. iRhoms are poten-
tial novel targets for TNF [5–7] and ADAM17/EGFR [8–10] related
pathologies, but their mode of action and druggability are unclear
(for more discussion see the article by Lemberg and Adrain in this
issue). The main mechanistic and structural model for the rhomboid
superfamily have been rhomboid proteases.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Investigation in as distant ﬁelds as parasitology, cancer biol-
gy or microbiology has revealed exciting functions for rhomboid
roteases in a variety of contexts. Although a large proportion of
his territory is still unexplored, the few examples below already
how that rhomboids are potential therapeutic targets. Investiga-
ion of biological roles of rhomboid proteases in multiple organisms
ould greatly beneﬁt from the availability of selective rhomboid
nhibitors, but these are currently not available. Here I review the
urrent strategies to inhibit rhomboid proteases and summarize
hat the ﬁeld has learned from them. I also review the current
nowledge of rhomboid mechanism and speciﬁcity, and discuss its
mplications for future strategies of rhomboid inhibitor develop-
ent. Let us ﬁrst focus on examples and contexts where rhomboid
roteases participate or can participate in disease-relevant pro-
esses and where selective rhomboid inhibitors could be employed
or pharmacological applications.
. Rhomboid proteases as potential future drug targets
.1. Microbial rhomboid proteases
Rhomboid proteases are present in a number of protozoan
arasites, such as Plasmodium, Toxoplasma, Eimeria, Cryptosporid-
um, Theileria and Babesia [11,12] including serious worldwide
athogens. Their functions have been addressed genetically
nd biochemically in Plasmodium, Toxoplasma, Entamoeba and
richomonas so far. In the extracellular protozoan parasite Tri-
homonas vaginalis, which causes a sexually transmitted infection
ggravating other disease conditions, rhomboid proteases TvROM1
nd TvROM3 are active enzymes, and overexpression of the cell-
urface localized TvROM1 enhances the association of the parasite
ith host cells and their lysis [13]. The extracellular parasite Enta-
oeba histolytica encodes one rhomboid protease EhROM1 that has
een implicated in adhesion and phagocytosis [14,15]. The intra-
ellular parasite Plasmodium falciparum causing malaria is probably
he most serious medical burden of the above named infectious
gents, affecting millions of people worldwide. The rhomboid pro-
eases PfROM1 and PfROM4 of P. falciparum can cleave and shed
everal major surface adhesins of the parasite that are implicated
n all stages of its life cycle [16]. Mutations in the transmembrane
omain of adhesin EBA-175 inhibiting its cleavage by PfROM4 pre-
ent the growth of the parasite [17], suggesting that PfROM4 is a
otential therapeutic target. In Plasmodium berghei, a genetically
ractable malaria model, PbROM1 deﬁciency did not compromise
he infectivity or pathogenicity, but genes encoding rhomboids
OM4, 6, 7 and 8 were refractory to deletion, suggesting that these
homboid proteases may  be essential for the parasite, at least in its
sexual blood stage [18]. Assuming that functions of the P. berghei
homboids will be conserved in P. falciparum,  there is an exciting
rospect that inhibitors of several rhomboid proteases could have
ntimalarial activity.
Beyond protozoan parasites, the rhomboid protease RbdA
rom Aspergillus fumigatus,  an opportunistic pathogenic mold
ncountered in immunocompromised individuals, is required
or the adaptation of A. fumigatus to hypoxia during infection
19]. The RbdA deﬁcient A. fumigatus is thus more sensitive to
hagocytic killing, elicits weaker immune response and exhibits
trongly attenuated virulence [19]. Since rhomboid proteases are
idespread, it is likely that other disease-relevant functions in
icrobes will be discovered. In particular, relatively little is known
bout the functions of rhomboid proteases in bacteria [20–23]
ompared to how very widely distributed across prokaryotes rhom-
oids are [3,24].pmental Biology 60 (2016) 52–62 53
2.2. Human rhomboid proteases
Rhomboid proteases are cardinal regulators of the EGF  receptor
signaling in Drosophila,  but initially it seemed that their function
in this pathway has not been conserved, because EGFR ligands
in mammals are known to be activated by the ADAM family
of membrane-bound metalloproteases [reviewed in Ref. [25,26]].
However, it is clear that the non-protease members of the rhom-
boid family of proteins called iRhoms control EGFR signaling in
mammals by activating ADAM17 [8,10,27–29], the main EGFR lig-
and activating enzyme, and there is accumulating evidence that
human rhomboid proteases may  participate in ﬁne-tuning of EGFR
signaling [30–32]. This elevates the interest in understanding the
role of mammalian rhomboid proteases in greater detail, and in
development of their inhibitors as research tools.
There are four rhomboid proteases located in the secretory
pathway of mammalian cells (‘secretase’ rhomboids RHBDL1-4)
and one in the mitochondria (PARL) [33]. The best studied human
secretase rhomboid is RHBDL2 (located at the plasma membrane
[34]), probably because it is the only RHBDL that readily cleaves
model rhomboid substrate Spitz [1] and has thus been amenable
to enzymological and cell biological investigation. RHBDL2 is
expressed mainly in epithelia [30], and it has been implicated
in wound healing [35], endothelial angiogenesis [36], EGF recep-
tor signaling [30,31], and possibly anoikis resistance [37], but
loss-of-function animal experiments addressing these suggested
functional hypotheses in vivo are lacking. Disease associations of
RHBDL2 have not been reported apart from a recently found cor-
relation between RHBDL2 mRNA levels and histological grade of
breast cancer tumors [38].
The second best studied human secretase rhomboid is RHBDL4
(also known as RHBDD1), which is located in the endoplasmic retic-
ulum. It has been implicated in membrane protein quality control
[39], and shown to secrete TGF [32,40] thus promoting the growth
of colorectal cancer cells via activation of the EGF receptor [32].
The grade of colorectal cancer biopsies from patients and survival
parameters correlated with RHBDL4 expression, and depletion of
endogenous RHBDL4 from tumor cells suppressed proliferation
in vitro and tumor growth in vivo [32], suggesting that inhibitors
of RHBDL4 could have anti-tumor properties.
The remaining two  human secretase rhomboids, RHBDL1 and
3 are the least characterized ones. They share about 49% sequence
identity, and display overlapping but non-identical expression pat-
terns, suggesting that they have distinct functions. RHBDL1 was
the ﬁrst human rhomboid protease gene to be identiﬁed [41]; it
is expressed mainly in the brain and kidney [41] and localized to
the Golgi apparatus [34]. RHBDL3 (also known as ventrhoid) is
expressed in the developing neural ventral tube and in the brain
[42], and is localized to the Golgi and plasma membrane [34]. It
is also expressed in the developing pancreas under control of the
neurogenin-3 transcription factor [43], but the signiﬁcance of this
observation for pancreas development and function is unclear. The
expression level of RHBDL3 has been correlated with the chrono-
logical age and it is one of a few candidate markers of aging brain
[44]. Both RHBDL1 and 3 bear all the sequence hallmarks of active
rhomboid proteases, and RHBDL3 is able to bind an activity-based
probe [45], suggesting that it has a functional active site. RHBDL1
and 3 might thus have a markedly different substrate speciﬁcity
from the model rhomboid proteases (such as RHBDL2), but since
no substrates of RHBDL1 and 3 have been identiﬁed so far, their
molecular functions remain unknown.
The mitochondrial rhomboid PARL is the best characterized
rhomboid protease in mammals. Mice deﬁcient in PARL have a
pronounced phenotype − muscle wasting and reduced lifespan −
caused by increased apoptosis [46]. The basis for this effect is that
PARL deﬁciency results in aberrant mitochondrial cristae, which
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acilitates the release of cytochrome C from mitochondria and sen-
itizes the parl −/- cells to intrinsic apoptotic stimuli [46], although
urther mechanistic details are unclear [47]. In fact, it turns out that
ARL is intimately involved in controlling mitochondrial health at
everal levels. Importantly, it is involved in the regulation of the
INK1-PARK2 pathway that promotes mitophagy by which aber-
ant mitochondria are degraded. Although the detailed role of PARL
n this process has been controversial, the most recent research
ndicates that PARL-catalysed cleavage of PINK1 leads to its degra-
ation in the cytoplasm and suppression of mitophagy [48]. Since
itochondrial dysfunction emerges as one of the main causes of
euronal loss in Parkinson’s disease [49], inhibition (partial loss of
unction) of PARL could stimulate mitophagy and alleviate neuronal
oss, thereby being beneﬁcial in Parkinson’s disease (PD). Other
ubstrates of PARL have been described and PARL has even been
roposed to function as a checkpoint of mitochondrial integrity
ipping the balance between mitophagy and repair on one hand
nd apoptosis on the other [47]. This is particularly relevant for
uman disease, because mitochondrial dysfunction is associated
ith a number of disease conditions including PD [reviewed in Ref.
50,51]] and type 2 diabetes [reviewed in Ref. [52]]. For more dis-
ussion on PARL refer to the article by DeStrooper in this issue.
aken together, the above examples demonstrate that selective
nd potent rhomboid inhibitors and a platform for their develop-
ent are urgently needed, both for research purposes to validate
unctional hypotheses and for potential pharmacological use.
. Rhomboid protease mechanism and speciﬁcity
Before we discuss the possibilities of inhibiting rhomboid pro-
eases, let us ﬁrst browse through what is known about rhomboid
echanism, because the principles of catalytic mechanism and
ubstrate speciﬁcity to a large extent determine the strategies for
nhibitor development.
.1. Catalytic mechanism
Most globular serine proteases, operating in an aqueous envi-
onment, use a catalytic triad, typically Asp-Ser-His, to abstract a
roton from the OH group of the catalytic Ser and thus poise it
or nucleophilic attack at a substrate peptide bond [53]. Rhomboid
roteases hydrolyse peptide bonds in transmembrane substrates
sing only a catalytic dyad of Ser and His [54] (Fig. 1A), which brings
ubstantial mechanistic differences. Molecular dynamics and quan-
um mechanics studies suggest that the lack of the third, proton
bstracting, residue makes the catalytic His254 of the E. coli rhom-
oid protease GlpG (hereinafter just GlpG) more acidic (i.e. it has
 lower pKa) than the OH group of Ser201 in the unliganded state
f the enzyme [55], which means that Ser201 is protonated in the
round state of the enzyme. Gradual desolvation of the active site
f GlpG by the incoming ligand (inhibitor or substrate) is thought
o induce an increase in the pKa of H254, leading to a concerted
roton abstraction from OH of Ser201 and nucleophilic attack
56]. In contrast, in classical serine proteases containing a catalytic
riad, such as chymotrypsin, the higher pKa of catalytic His facili-
ates deprotonation of catalytic Ser and nucleophilic attack can be
nergetically and temporally separated into distinct catalytic steps
56]. This hypothesis could explain the markedly low catalytic efﬁ-
iency of GlpG compared to classical serine proteases chymotrypsin
r trypsin, but it is less clear what its implication for rhomboid
nhibitor design might be.Another difference of rhomboid mechanism from the mecha-
ism of classical serine proteases is that the hydroxyl of the catalytic
erine of rhomboid carries out the nucleophilic attack of the prochi-
al carbonyl carbon of the scissile bond from its si-face [54,57,58]pmental Biology 60 (2016) 52–62
(Fig. 1B), while most serine proteases attack the re-face of carbonyl
carbon [59] apart from few exceptions such as the E. coli leader pep-
tidase [60,61]. These stereochemical differences might be exploited
in the design of rhomboid-speciﬁc inhibitors.
The structures of the DFP and peptidyl aldehyde inhibitor com-
plexes with GlpG show that the negatively charged oxygen of the
covalent tetrahedral intermediates of the reaction (Fig. 1A) is sta-
bilised by hydrogen-bonding to the side-chains of amino acids
H150 and N154 and the main-chain amide of S201 in a structure
termed ‘oxyanion pocket’ [62] (Fig. 1C).
Rhomboid-catalyzed reaction occurs in the lipid membrane, and
the reaction mechanism involves a covalent intermediate acyl-
enzyme that must be hydrolyzed to complete the reaction cycle.
The catalytic dyad of rhomboid is about 10 Å below the mem-
brane surface [54]. The active site is open to bulk solvent, and
the delivery of water molecules for the deacylation reaction thus
seems unhindered [57]. Intriguingly however, molecular dynamics
studies suggest that a cavity near the catalytic serine might act as
a ‘water retention site’ (Fig. 1D) that facilitates delivery of water
molecules from bulk solution into the membrane-immersed cat-
alytic center, thus potentiating catalytic efﬁciency of GlpG [63]. This
hypothesis is supported by mutagenesis experiments where muta-
tions of amino acids with polar side chains that were suggested to
constitute a ‘relay‘ mechanism for water molecules (mainly Q189
and S185) decrease catalytic activity of GlpG without impacting on
its thermodynamic stability [63]. It is attractive to speculate that an
accessory mechanism for water delivery into the active site could
be a general feature of intramembrane proteases.
3.2. Substrate speciﬁcity
A separate question important for inhibitor design is that of how
rhomboid proteases recognize their substrates. Intramembrane
protease substrates are transmembrane -helices, and although
protease cleavage sites located apparently within secondary struc-
tures such as helices have been described [64], these presumably
need to be unwound before protease cleavage, because most or
all protease active sites bind substrates or inhibitors in extended
-strand conformations [65,66]. According to this view, intramem-
brane proteases including rhomboids were initially thought not to
be sequence-speciﬁc and to recognize primarily the intrinsic insta-
bility of transmembrane helices at the site of cleavage, deﬁned by
the presence of residues with low transmembrane helical propen-
sity [67]. The intrinsic helical instability was  initially thought to be
the key feature deﬁning rhomboid substrates [68], but this condi-
tion was insufﬁcient to predict substrates, and did not explain the
position of the cleavage site [69].
Later it was  found that small amino acids were preferred by GlpG
at the P1 position of the substrate [69], suggesting that rhomboids
displayed some level of sequence speciﬁcity. Indeed, detailed com-
parative analysis of cleavage kinetics and site-speciﬁcity using the
ﬁrst natural substrate of a bacterial rhomboid [20] ﬁnally revealed
that rhomboids recognize two  elements in their substrates [70]
(Fig. 2 A), one of which is the hydrophobic helical transmembrane
domain (TMD) and the second one is a linear sequence of about 6
amino acids that binds into the active site and determines the site
of cleavage (also called ‘recognition motif’). The recognition motif
can be part of the TMD  of the substrate or be adjacent to it; hence
the two elements are separable [70]. Numerous rhomboids were
found to prefer small amino acids in the P1 position, while there
is more diversity in sequence preferences at other positions. Some
bacterial rhomboids including GlpG, AarA and YqgP prefer large
hydrophobic residues in the P4 and P2′ positions [70]. This ﬁnd-
ing was  conﬁrmed by structures of peptidyl chloromethylketone
[71] and peptidyl aldehyde [72] inhibitors comprising the P4-P1
residues in complex with GlpG (Fig. 2B and C). In addition, E.coli
K. Strisovsky / Seminars in Cell & Developmental Biology 60 (2016) 52–62 55
Fig. 1. Reaction mechanism of rhomboid proteases.
A) Catalytic reaction cycle of rhomboid protease. A P1–P1′ segment of the substrate is shown.
B)  Molecular dynamics based model of the scission complex of the P4 to P3′ segment of the substrate [71] demonstrates the si-face attack of the prochiral carbonyl carbon
of  the substrate by the hydroxyl of the catalytic serine 201 of GlpG. The substrate is shown as green sticks, the enzyme is in grey.
C)  Interaction of the oxyanion in the tetrahedral intermediate with the ‘oxyanion hole’ in GlpG formed by the side chains of conserved amino acids H150 and N154 and the
main-chain amide of S201 as revealed by the crystal structure of GlpG complexed to diisopropylﬂuorophosphate (DFP; PDB code 3txt; protein backbone in yellow; ligand in
thin  sticks, ligand carbons in yellow) and peptidyl aldehyde (PDB code 5f5b; protein backbone in gray; ligand in thick sticks, ligand carbons in green). The hydrogen bonds
stabilising the oxyanion in the peptidyl aldehyde complex structure are denoted by dashed lines. Note that the position of the oxyanion is nearly identical in both ligands.
D)  The detail of the ‘water retention site’ that was proposed to enhance catalytic efﬁciency of rhomboid protease GlpG [63]. Structure of GlpG apoenzyme (2xov) is shown
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gs  grey surface with the three water molecules (red) proposed to be important for 
f  the L5 loop overhanging the active site has been removed for clarity. The side-ch
heir  transfer from the bulk solvent.
lpG prefers positively charged residues in the P3 and P2 positions
71,72]. The sequence preferences at different positions around
he scissile bond, i.e. the recognition motif itself, might thus dif-
er among rhomboid proteases, and this may  contribute to their
ifferent substrate speciﬁcities.
The TMD  of the substrate was suggested to ﬁrst interact with
n ‘intramembrane exosite’ of rhomboid, followed by a conforma-
ional change that might involve local unfolding of substrate TMD
nd binding of the recognition motif region into rhomboid active
ite, resulting in scission [70] (Fig. 2A). This model is supported
y several independent lines of evidence. First, separating the sub-
trate TMD  and recognition motif with a linker of increasing length
radually decreased the initial reaction rate [70]. Second, kinet-nzyme hydrolysis located in a shallow cavity near the catalytic dyad (yellow). Part
own in green have been proposed to stabilise these water molecules and facilitate
ics measurements in lipid membranes revealed that mutations in
the recognition motif of TatA decreased the kcat of AarA by two
orders of magnitude with only minor effect on KM [73]. And ﬁnally,
active site directed peptidyl aldehydes inhibit the cleavage of trans-
membrane substrate by a non-competitive mechanism, or in other
words, the inhibitor can bind to an enzyme-substrate complex [72].
These lines of evidence collectively imply that the TMD  of the sub-
strate binds the enzyme ﬁrst into a site that is spatially separated
from the active site, which fulﬁls the deﬁnition of an exosite [74],
and then the recognition motif interacts with the active site leading
to the proteolytic reaction, as proposed earlier [70].
This two-step mechanism implies that the Michaelis complex
of rhomboid reaction (i.e. the enzyme-substrate complex that is in
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Fig. 2. Substrate recognition by rhomboid proteases.
A) Schematic model of events along the reaction co-ordinate of rhomboid catalysis. This model draws on the current consensus in the ﬁeld assuming that the transmembrane
domain of the substrate makes ﬁrst contact with rhomboid protease within lipid membrane (docking/interrogation complex). Only then does a linear sequence deﬁning the
cleavage site (recognition motif) interact with rhomboid active site, forming the scission complex that aligns the polypeptide in the active site for the actual proteolytic
reaction to follow. The postulated intramembrane exosite is highlighted in brown, the recognition motif region in blue and catalytic dyad in red.
B)  Structure of the complex of peptidyl chloromethylketone AcIATAcmk with GlpG (4qo2) was the ﬁrst model of the acyl-enzyme and tetrahedral intermediate [71].
Chloromethylketones react covalently with both the catalytic Ser and His (Fig. 3D), forming a doubly bound tetrahedral uncharged species bearing similarity to the second
tetrahedral intermediate (forming during hydrolysis of the acyl-enzyme).
C) Structure of the complex of peptide aldehyde AcVRMAcho with GlpG (5f5b), the best available model of the second tetrahedral intermediate [72].
D)  Model of the scission complex of rhomboid based on the crystal structure of a substrate peptide chloromethyketone complex (4qo2), molecular dynamics [71] and
manual  docking of a model transmembrane helix of Providencia stuartii TatA. Aquiring experimental data on the structures of the transmembrane domain of the substrate
in  the docking and scission complexes is the key missing element needed for the full understanding of the mechanism and speciﬁcity of rhomboid protease.
E)  The spatial relationship of the proposed water retention site and S1 subsite in GlpG. The water retention site and the S1 subsite (both demarkated by dashed lines) are
part  of a contiguous cavity inside GlpG that is displayed as a surface in the structure of the complex of peptidyl aldehyde AcVRMAcho with GlpG (5f5b). The cavity surface
is  colored by hydrophobicity based on the YRB scheme [97] such that aliphatic hydrophobic carbons contribute yellow, negatively charged surfaces are red and positively
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hermodynamic equilibrium with free enzyme and substrate [75])
s actually the ﬁrst encounter complex interacting via the trans-
embrane regions of enzyme and substrate in which rhomboid
ctive site is unoccupied [72]. Since the term Michaelis complex is
ften used in a slightly different meaning, as the immediate pre-
cission complex of the enzyme and substrate poised for catalysis
55,71,76], I herein instead adhere to the perhaps more explicitly
escriptive terms the ‘docking’ [77] or ‘interrogation’ [73] complex
Fig. 2A) for the ﬁrst encounter complex, and ‘scission’ complex for
he next stage complex where the substrate’s recognition motif is
ully aligned in the active site of rhomboid (Fig. 2A). It is tempting
o speculate that other rhomboid-superfamily proteins including
Rhoms and Derlins might share similar principles of recognition
f their client proteins or substrates (see the article by Lemberg
nd Adrain in this issue for more discussion).
These two  separable recognition features of rhomboid sub-
trates operate in concert and are conformationally coupled. In
act, the intimate connection between the lipid membrane and
tructural dynamics of the transmembrane domain of substrate
ay  lie at the very heart of intramembrane protease mechanism
78]. Consistent with this idea, it has been demonstrated that
embrane environment can inﬂuence the speciﬁcity of rhom-
oid protease: proteins that are normally non-substrates become
leaved by rhomboid upon disturbing the membrane properties
hemically [79,80]. Similarly, perturbing the helicity of the TMD
f a non-substrate by introducing prolines along the TMD  turns it
nto a substrate [80]. In summary, there is a gradual convergence of
pinions in the ﬁeld which crystallizes in a model when two recog-
ition elements deﬁne rhomboid substrates [70] and the structural
ynamics of the substrate that determines their accessibility to
homboid is profoundly inﬂuenced by the membrane environment
79].
The questions that remain to be answered to understand
ntramembrane proteolysis by rhomboid proteases at atomic level
oncern the extent of the interaction surface between the enzyme
nd substrate, the identity of the hotspots or regions that determine
he binding energy, and the structure of the full substrate-enzyme
omplex. The ﬁrst steps to the structural characterization of
he substrate-enzyme complex were made recently. The X-ray
tructures of substrate-derived peptidyl chloromethylketone [71]
Fig. 2B) and peptidyl aldehyde inhibitors [72] (Fig. 2C) complexed
o GlpG mimic  the acyl-enzyme and the second tetrahedral inter-
ediate. These structures have revealed the mode of binding of
he P4 to P1 residues into the corresponding subsites in the active
ite, and yielded a molecular model of the P4 to P3′ fragment of
he ‘scission’ complex [71] (Fig. 2D). This part of the substrate (the
ecognition motif) binds into the active site as a parallel -strand
ith the L3 loop of GlpG stabilized by a number of hydrogen bonds
nd van der Waals interactions (Fig. 2E and F). The P1 residue points
nto a well-deﬁned S1 subsite cavity, and the P4 residue interacts
ith the L1 loop. The implications of these ﬁndings for inhibitor
esign will be discussed in Section 5.2, and the implications for the
unction of the L1 loop region in other rhomboid-family proteins
re discussed in more detail by Lemberg and Adrain in this issue.
. Rhomboid activity assaysInhibitor development requires robust activity assays for scor-
ng of inhibitor efﬁciency and afﬁnity. The ﬁrst widely used in vivo
r in vitro activity assays employed model transmembrane pro-
harged ones are in blue. The side-chains of residues proposed to stabilize the water mole
he  rest of the peptide ligand is in grey. The S1 subsite has a hydrophobic surface, which i
)  The structure of peptidyl aldehyde AcVRMAcho complexed to GlpG (5f5b) shows the n
cheme  [97]), the ligand is in green, and the subsites are approximated by dashed lines. Tpmental Biology 60 (2016) 52–62 57
tein substrates and SDS-PAGE based readout [70,81–84]. While this
is an accurate and reproducible assay for the analysis of inhibi-
tion [71,85], it is also low-throughput, relatively time-consuming,
and allows only an endpoint analysis of the reaction. An interest-
ing variation of this assay employs detection and quantitation of
reaction products by mass spectrometry [86]. This assay however
requires an expensive instrument for detection and is not continu-
ous, which limits its practical use. Substrates that allow continuous
assays and measurement of initial reaction rates using optical read-
out are much more practical, but it has taken surprisingly long time
to develop them.
A generic ﬂuorogenic protease substrate, internally quenched
BODIPY-casein, has been reported to be cleaved by GlpG [54,82],
but the sites of cleavage are unknown, casein is a completely het-
erologous substrate lacking a transmembrane domain, and thus
does not mimic the interactions of a true rhomboid substrate.
While this might not be a problem for detecting active site directed
inhibitors, any inhibitors binding into the exosite region might not
be detected. More native and advanced assays that enable mea-
surement of enzyme kinetics use ﬂuorogenic peptide or protein
substrates: a FRET derivative of the truncated Gurken substrate
[85], a genetically encoded transmembrane FRET substrate based
on a CyPet-TatA-YPet recombinant fusion protein [87] or FITC
labelled TatA transmembrane peptide [73]. Each of these assays
has its limitations: some work only for a speciﬁc rhomboid pro-
tease [85], others are usable only in liposomes [73], and yet others
have a limited choice of ﬂuorophores, are relatively large and have
a low FRET efﬁciency [87].
An alternative tool to substrate cleavage assays for detection of
proteases and their inhibitors are activity based probes [88]. A ﬂu-
orescence polarization assay with activity based probes has been
reported for rhomboid proteases, and was used to identify new -
lactone type inhibitors [89] (discussed in more detail in Section 5.2).
Signiﬁcant advantage of these phosphonoﬂuoridate probes is that
they are relatively unselective, and might be usable for virtually any
rhomboid protease. On the other hand, ﬂuorescence polarization
is prone to detergent artifacts, and an active-site directed probe
would most likely not detect an exosite-directed inhibitor. There
is thus a need for a strategy to generate small ﬂuorogenic trans-
membrane substrates that would capture all the relevant enzyme
substrate interactions, be more general or more speciﬁc for a par-
ticular rhomboid protease as needed, be operating at red-shifted
wavelengths to be suitable for high-throughput screening of com-
pound libraries, and allow fast and continuous measurements in
detergent as well as liposomes.
5. Rhomboid inhibitors
5.1. The beginnings
The discovery that rhomboid is a serine protease had been aided
by the sensitivity of the founding member Drosophila rhomboid-1
to serine protease inhibitors dichloroisocoumarin (DCI) and tosyl
phenylalanyl chloromethylketone (TPCK) [1]. The ﬁrst structural
insights into the mechanism and speciﬁcity of rhomboid have been
gained from crystallographic studies of general serine protease
inhibitors diisopropylﬂuorophosphate [90], isocoumarins [90,91]
and a phosphonoﬂuoridate [92] (Fig. 3A and B). These studies have
revealed the oxyanion hole (Fig. 1C) and the likely S1 subsite of
rhomboid protease, but since the inhibitors were very dissim-
cules (red), the catalytic dyad and the P1 residue of the ligand are shown in green,
s consistent with a strong preference for Ala in the P1 position by GlpG [71,91].
on-prime subsites of GlpG. The surface of GlpG is colored by hydrophobicity (YRB
he S4 subsite is formed by residues of the L1 loop.
58 K. Strisovsky / Seminars in Cell & Developmental Biology 60 (2016) 52–62
Fig. 3. The main classes and examples of rhomboid protease inhibitors. Reaction mechanisms with stereochemistry adjusted for rhomboid proteases (derived from the 3D
structures of inhibitor complexes with GlpG) are displayed as well as 3D structures of the inhibitor complexes and GlpG indicating the binding mode. Note that an isocoumarin
covalently binds to His150 (3zeb) instead of the more common His254 (2xow), and that a phosphonoﬂuoridate (3ubb), isocoumarin (3zeb) and a -lactam (3zmi) bind into
the  prime side of rhomboid active site. A) phosphonoﬂuoridates [90,92], B) isocoumarins [86,91], C) -lactams and -lactones [85,89,94], D) peptidyl chloromethylketones
[71], and E) peptidyl aldehydes [72]. The reversibility of binding of peptidyl aldehydes is denoted by a reverse arrow.
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lar from a peptide substrate, they were not more informative
bout rhomboid mechanism and speciﬁcity. All of these inhibitors
re based on a very reactive electrophile, hence likely to inhibit
ther serine proteases, and they should deﬁnitely not be used as
homboid-speciﬁc inhibitors in cell biological studies (which DCI
ometimes is, e.g. [35,37]). The lack of selectivity is a disadvantage
or cell biological use, but it is a distinct advantage for the genera-
ion of activity-based probes (ABPs) useful for a general rhomboid
ssay [45,86,89,93] (discussed in Section 4).
Improvements of rhomboid activity assays enabled screening
f compound libraries for rhomboid inhibitors. A high-throughput
ssay of about 60,000-compound library with a ﬂuorogenic FRET
ubstrate and AarA revealed monocyclic -lactams as new rhom-
oid inhibitors [85] (Fig. 3C). These compounds covalently bind the
atalytic serine of GlpG, show time-dependence of inhibition, slow
eversibility, and their potency in vitro is low micromolar or sub-
icromolar on Providencia stuartii AarA and E. coli GlpG (under a
0 min  pre-incubation with the enzyme) [85]. They display some
electivity between GlpG and AarA over chymotrypsin [85], but
heir activity in vivo is limited, and even at high micromolar con-
entrations -lactams do not inhibit the endogenous E. coli GlpG
ully [85]. This could reﬂect the fact that the complexes of the
onocyclic -lactams with GlpG slowly hydrolyse in a way that
eads to the inactivation of the inhibitor, because the -lactam ring
s not reformed spontaneously in solution. -lactams are there-
ore in fact slowly turned over by rhomboid and act rather as
failed-suicide substrates’. Crystallographic analyses of complexes
f these compounds with GlpG show that they occupy the prime
ide of rhomboid active site, possibly the S2′ subsite [94] (Fig. 3C).
tructure-activity relationship analysis has indicated how mono-
yclic -lactams could be modiﬁed to enhance their selectivity [85],
ut surprisingly these compounds have not been developed further
o far.
A lot of inhibitor development effort has since then focused
n isocoumarins. Screening of a library of electrophiles includ-
ng isocoumarins, phosphonates and sulphonyl ﬂuorides using a
ALDI mass-spectrometry based assay yielded several new iso-
oumarins that were developed into activity-based probes [86]. In
n effort to identify new electrophile chemistries that would be
ctive as rhomboid inhibitors, a small library of 85 compounds
f reactive electrophiles including isocoumarins, phosphonates,
hosphoramidates, -sultams, -lactones, epoxides and thiiranes,
as been screened using a novel activity assay based on ABP ﬂu-
rescence polarization [89]. The -lactones have been thereby
dentiﬁed as a new class of rhomboid inhibitors (Fig. 3C). They are
tructurally similar to the -lactams, are relatively weak inhibitors
ith apparent IC50 in high micromolar range against rhomboid,
ut -lactone inhibitors and ABPs at least show some selectivity
mong rhomboids [45]. The inhibition properties of isocoumarins,
-lactams and -lactones can probably be further improved, but
nsufﬁcient selectivity will probably be a persistent problem with
socoumarins due to their high reactivity and irreversible chem-
stry, generally undesired for pharmacological use. The -lactams
eem the best candidates for further development, but given their
imited stability and in vivo activity discussed above, there is deﬁ-
itely a clear scope to explore the chemical space for new, potent
nd selective rhomboid inhibitors.
.2. Structure and mechanism based design and future directions
The desire to understand the structural basis of rhomboid
peciﬁcity and sequence preferences [70] has led to the design
f substrate-derived peptidyl chloromethylketone inhibitors [71]
Fig. 3D). These compounds interacted with GlpG in a substrate-
ike manner, and their co-crystal structures with GlpG offered the
rst structural insight into the mode of substrate binding to rhom-pmental Biology 60 (2016) 52–62 59
boid, or in fact, any intramembrane protease [71] (discussed also
in Section 3.2). Recent work shows that the active site of rhomboid
can accommodate about 6 residues (P4 to P2′), and displays distinct
sequence preferences at several positions [70,71] Most observa-
tions made from the structures of peptidyl chloromethylketones
[71] have been independently conﬁrmed by recent structures of
GlpG complexed to peptidyl aldehydes [72] (Fig. 3E), and these
two studies together pave the way for a next generation of rhom-
boid inhibitors based on an oligopeptide (or its mimic) coupled
to a suitable electrophilic warhead. Their rational design will be
undoubtedly guided by structure of their complexes with GlpG and
may  be aided by an improved understanding of rhomboid mecha-
nism (discussed in Section 3.1).
The crystal structures of the complexes of GlpG with the pep-
tide inhibitors have spurred a speculative hypothesis that rests in
the fact that GlpG shows a strict preference for small amino acids
in the P1 position (such as Ala), but the S1 subsite is a larger cavity
into which larger residues could theoretically be accommodated.
Interestingly, the ‘deeper’ parts of the S1 subsite coincide with the
previously postulated water retention site [63] (discussed in Sec-
tion 3.1) (Fig. 2E). It is therefore possible that small amino acids
in the P1 position are preferred by rhomboids because larger ones
might interfere with the water transfer from the retention site to
the catalytic dyad during the catalytic cycle [71]. If this mechanism
is conﬁrmed, modiﬁcation of the P1 residue of the inhibitor such
that it allows binding into the S1 subsite but restricts or blocks
water transfer from the water retention site would constitute an
entirely new mechanism to increase the selectivity of rhomboid
inhibitors.
All the so far discussed rhomboid inhibitors covalently bind
one or both residues of the catalytic dyad via a reactive elec-
trophilic group. This strategy in principle may  limit selectivity,
because many other serine proteases (or hydrolases in general)
employing similar catalytic chemistry might be also affected by
these compounds. None of the so far developed rhomboid inhibitors
have been tested for selectivity beyond measuring their effect on
common digestive proteases chymotrypsin or trypsin [85,86]. In
general, a more reactive electrophilic ‘warhead’ leads to a more
potent inhibitor, but with a lower selectivity. In practice, selectivity
can be improved by target-speciﬁc modiﬁcation of the inhibitor. A
big challenge for future studies will thus be controlling and improv-
ing inhibitor selectivity while maintaining potency. One strategy
could be to use a less reactive electrophilic warhead while adding
speciﬁcity-determining moieties to ensure tight binding. Exploit-
ing the knowledge of rhomboid mechanism and subsite preferences
[70–73], sequence-optimized oligopeptides or their mimics could
be explored that will be coupled to a variety of electrophiles that
have been successfully used in protease inhibitors and are even
clinically used, such as peptidyl boronates, nitriles, or various
activated ketones [reviewed in [53,95]]. In addition, since some
isocoumarins and -lactams bind into the prime side of rhomboid
active site (Fig. 3B and C), designing inhibitors that would occupy
both the prime and non-prime sides of the active site could increase
their afﬁnity and selectivity.
If we  think beyond active-site directed inhibitors, we realize
that binding of substrate TMD  at an intramembrane exosite [70,71]
(also called an ‘interrogation site’ [72,73]) of GlpG is the ﬁrst step
in catalysis, which suggests that exosite-directed non-covalent
inhibitors might be an alternative. Indeed, helical peptides have
been designed that efﬁciently inhibit -secretase [96], and their
mechanism of action likely involves binding into an initial ‘docking
site’, supporting the general feasibility of this approach. It is uncer-
tain whether such compounds could in principle achieve selectivity
for rhomboids, because recent work suggests that binding at the
rhomboid docking site/exosite might be relatively weak and not
very selective [73]. Nonetheless, this area is certainly worth explor-
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ng further, and development of more efﬁcient activity assays that
ould detect binding to the intramembrane exosite while being
uitable for high-throughput screening would greatly facilitate this
ffort.
. Concluding remarks and perspectives
Rhomboid intramembrane proteases are becoming increas-
ngly attractive in disease contexts, but the development of their
nhibitors has lagged behind. It will be important to develop selec-
ive and potent inhibitors of rhomboids both for exploration and
alidation of their physiological roles and for prospective drug
evelopment. These efforts will be aided by improved activity
ssays and deeper mechanistic and structural understanding of
homboid proteases. The near future could bring further develop-
ent of existing covalently binding scaffolds such as the -lactams,
iscovery of new covalent active site directed inhibitors as well as
ovel, exosite-binding or allosteric inhibitors.
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